Brief: Athira Pharma Announces Formation Of Scientific Advisory Board
Brief: Athira Issues Statement In Response To Richard Kayne's Suspension Of His Proxy Contest
Athira Pharma Inc reports results for the quarter ended in March - Earnings Summary
Athira Pharma Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Athira Pharma Extends Ongoing Open Label Extension Study For Lift-Ad And Act-Ad Clinical Trials Of Fosgonimeton (Ath-1017) For Mild To Moderate Alzheimer’S Disease
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Athira Shareholders Vote “For” All Of Athira’S Highly Qualified Director Nominees
Brief: Athira Pharma Inc - Urges Shareholders To Vote “For” Co's Independent Director Nominees – Joseph Edelman, John Fluke, Jr. And Grant Pickering
Brief: Athira Pharma Says ISS Has Recommended That Shareholders Vote On Athira’s White Proxy Card
Brief: Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is Required
Brief: Athira Pharma Urges Shareholders To Vote "For" Director Nominees Joseph Edelman, John Fluke Jr And Grant Pickering
Brief: Athira Pharma Files Definitive Proxy Statement And Mails Letter To Shareholders
Brief: Athira Pharma Doses First Subject In Phase 1 Clinical Trial Of HGF/MET Positive Modulator, ATH-1020, An Orally Available Small Molecule For Neuropsychiatric Conditions
Billionaire investor launches board fight at Athira, wants CEO replaced (updated)
Billionaire investor launches board fight at Athira, wants CEO replaced
Athira Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Athira Pharma Reports Full Year 2021 Results
Athira Pharma Inc expected to post a loss of 54cents a share - Earnings Preview
Brief: Athira Pharma Announces Appointment Of Michael A. Panzara To Its Board Of Directors
Brief: Athira Pharma Announces Appointment Of Grant Pickering To Its Board Of Directors